NASDAQ:PNT

POINT Biopharma Global (PNT) Stock Forecast, Price & News

$6.68

+0.01 (+0.15%)

(As of 10/2/2023 ET)

Compare

Today's Range: $6.57
▼
$6.86
50-Day Range: $6.67
▼
$9.10
52-Week Range: $5.59
▼
$11.13

Volume: 604,881 shs
Average Volume: 620,135 shs
Market Capitalization: $707.07 million

P/E Ratio: 7.68
Dividend Yield: N/A
Price Target: $14.33

POINT Biopharma Global MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 114.4% Upside
$14.33 Price Target
Short Interest: Bearish
8.17% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.28
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.00) to ($0.71) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.33 out of 5 stars

Medical Sector

307th out of 969 stocks

Pharmaceutical Preparations Industry

123rd out of 452 stocks

3.5

Analyst's Opinion

Consensus Rating
POINT Biopharma Global has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $14.33, POINT Biopharma Global has a forecasted upside of 114.4% from its current price of $6.69.
Amount of Analyst Coverage
POINT Biopharma Global has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
8.17% of the float of POINT Biopharma Global has been sold short.
Short Interest Ratio / Days to Cover
POINT Biopharma Global has a short interest ratio ("days to cover") of 12.8, which indicates bearish sentiment.
Change versus previous month
Short interest in POINT Biopharma Global has recently decreased by 0.14%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
POINT Biopharma Global does not currently pay a dividend.
Dividend Growth
POINT Biopharma Global does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PNT.

4.0

News and Social Media Coverage

News Sentiment
POINT Biopharma Global has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for POINT Biopharma Global this week, compared to 1 article on an average week.
Search Interest
5 people have searched for PNT on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.
MarketBeat Follows
4 people have added POINT Biopharma Global to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, POINT Biopharma Global insiders have not sold or bought any company stock.
Percentage Held by Insiders
16.00% of the stock of POINT Biopharma Global is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
59.53% of the stock of POINT Biopharma Global is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for POINT Biopharma Global are expected to grow in the coming year, from ($1.00) to ($0.71) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of POINT Biopharma Global is 7.68, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 111.64.
Price to Earnings Ratio vs. Sector
The P/E ratio of POINT Biopharma Global is 7.68, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 114.66.
Price to Book Value per Share Ratio
POINT Biopharma Global has a P/B Ratio of 1.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About POINT Biopharma Global (NASDAQ:PNT) Stock

POINT Biopharma Global Inc., a radiopharmaceutical company, develops and commercializes radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-alpha inhibitor targeting program being developed for use in various tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.

PNT Price History

30 days | 90 days | 365 days | Advanced Chart

PNT Stock News Headlines

September 30, 2023 | finance.yahoo.com

Will Weakness in POINT Biopharma Global Inc.'s (NASDAQ:PNT) Stock Prove Temporary Given Strong Fundamentals?

September 29, 2023 | markets.businessinsider.com

Point Biopharma Global: Promising Phase III Data and Potential Market Share Capture

October 2, 2023 | Behind the Markets (Ad)

[BREAKING] New "Living Missile" to Replace Nuclear Missiles

CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!

September 27, 2023 | markets.businessinsider.com

EQS-Adhoc: Eckert & Ziegler Signs Strategically Important Agreement for the Supply of Lutetium-177 with POINT Biopharma

September 18, 2023 | finance.yahoo.com

POINT Biopharma and Athebio Announce Partnership to Develop Designed Ankyrin Repeat Protein Targeted Radioligands

August 20, 2023 | finance.yahoo.com

POINT Biopharma Global Inc. (NASDAQ:PNT) Analysts Are More Bearish Than They Used To Be

August 14, 2023 | finance.yahoo.com

POINT Biopharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights

August 2, 2023 | seekingalpha.com

POINT Biopharma: Leading The Future Of Radioligand Therapy

October 2, 2023 | Behind the Markets (Ad)

[BREAKING] New "Living Missile" to Replace Nuclear Missiles

CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!

August 1, 2023 | finance.yahoo.com

With 50% institutional ownership, POINT Biopharma Global Inc. (NASDAQ:PNT) is a favorite amongst the big guns

August 1, 2023 | seekingalpha.com

POINT Biopharma: Stock Has Upcoming Catalysts With 2 Therapies In Phase 3 Trials

July 31, 2023 | finance.yahoo.com

ITM and POINT Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177

July 15, 2023 | fool.com

Point Biopharma Global (NASDAQ: PNT)

June 26, 2023 | finance.yahoo.com

POINT Biopharma Expands Its Research with Next-Generation Isotopes, Publishing New Preclinical Data at SNMMI’s Annual Congress

June 26, 2023 | finance.yahoo.com

POINT Biopharma and AdvanCell to Collaborate in the Development of Lead-212-Labeled Radioligands

June 22, 2023 | markets.businessinsider.com

SVB Securities Sticks to Their Buy Rating for POINT Biopharma Global (PNT)

June 12, 2023 | finance.yahoo.com

POINT Biopharma Announces Appointment of Dr. Bridget Martell to its Board of Directors

June 7, 2023 | finance.yahoo.com

POINT Biopharma to Host Virtual Investor Day on Tuesday, June 20, 2023

May 25, 2023 | finance.yahoo.com

POINT Biopharma Announces FRONTIER Trial-in-Progress Poster Presentation at ASCO

May 19, 2023 | seekingalpha.com

POINT Biopharma: Navigating The Radioligand Therapy Landscape With Strong Financials

May 17, 2023 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: POINT Biopharma Global (PNT), NewAmsterdam Pharma Company (NAMS)

May 16, 2023 | msn.com

Oppenheimer Reiterates POINT Biopharma Global (PNT) Outperform Recommendation

May 15, 2023 | msn.com

Why Shares of Point Biopharma Global Rose Monday

May 15, 2023 | finance.yahoo.com

POINT Biopharma Reports First Quarter 2023 Financial Results and Provides Business Highlights

May 15, 2023 | finance.yahoo.com

POINT Biopharma Makes Strategic Investment in Commercial-Scale Alpha-Emitting Isotope Manufacturer

May 14, 2023 | investing.com

POINT Biopharma Global (PNT) Earnings Dates & Reports

May 10, 2023 | finance.yahoo.com

Are Investors Undervaluing POINT Biopharma Global Inc. (NASDAQ:PNT) By 46%?

See More Headlines

Receive PNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for POINT Biopharma Global and its competitors with MarketBeat's FREE daily newsletter.

PNT Company Calendar

Last Earnings: 8/14/2023
Today: 10/02/2023
Next Earnings (Estimated): 11/13/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:PNT
CUSIP: N/A
CIK: 1811764
Web: www.pointbiopharma.com
Phone: 64-7812-2417
Fax: N/A
Employees: 129
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $14.33
High Stock Price Forecast: $16.00
Low Stock Price Forecast: $13.00
Forecasted Upside/Downside: +114.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.87
Trailing P/E Ratio: 7.68
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $98.29 million
Net Margins: N/A
Pretax Margin: 52.79%
Return on Equity: 22.69%
Return on Assets: 19.86%

Debt

Debt-to-Equity Ratio: 0.01
Current Ratio: 10.51
Quick Ratio: 10.51

Sales & Book Value

Annual Sales: $226.58 million
Price / Sales: 3.12
Cash Flow: $0.94 per share
Price / Cash Flow: 7.10
Book Value: $4.68 per share
Price / Book: 1.43

Miscellaneous

Outstanding Shares: 105,770,000
Free Float: 88,843,000
Market Cap: $707.07 million
Optionable: Not Optionable
Beta: 0.22

10 Best Stocks to Own in 2023

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Allan Charles Silber (Age 73)
Exec. Chairman
Comp: $1.02M

Dr. Joe A. McCann Ph.D. (Age 45)
CEO & Director
Comp: $1.06M

Dr. Neil E. Fleshner FRCSC (Age 59)
M.D., M.PH, Chief Medical Officer & Director
Comp: $318.49k

Ms. Jessica D. Jensen M.P.H. (Age 42)
MPH, Exec. VP of Clinical Devel.
Comp: $816.17k

Mr. Bill Demers B.B.A. (Age 64)
F.C.A., FCPA, CFO & Corp. Sec.

Ms. Justyna Kelly M.Sc. (Age 38)
Chief Operating Officer

Ms. Jazz Braich
SVP of People & Culture

Mr. Ari Shomair
VP of Corp. Affairs & Chief of Staff

Dr. Myra Rosario Herle Ph.D.
R.Ph., Exec. VP of Regulatory Affairs

Dr. Matthew P. Vincent J.D.
Ph.D., Sr. VP of Bus. Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PNT Stock - Frequently Asked Questions

Should I buy or sell POINT Biopharma Global stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for POINT Biopharma Global in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PNT shares.
View PNT analyst ratings or view top-rated stocks.
What is POINT Biopharma Global's stock price forecast for 2023?: 5 Wall Street research analysts have issued twelve-month price objectives for POINT Biopharma Global's stock. Their PNT share price forecasts range from $13.00 to $16.00. On average, they expect the company's stock price to reach $14.33 in the next twelve months. This suggests a possible upside of 114.4% from the stock's current price.
View analysts price targets for PNT or view top-rated stocks among Wall Street analysts.
How have PNT shares performed in 2023?: POINT Biopharma Global's stock was trading at $7.29 at the beginning of 2023. Since then, PNT stock has decreased by 8.3% and is now trading at $6.6850.
View the best growth stocks for 2023 here.
When is POINT Biopharma Global's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our PNT earnings forecast.
How were POINT Biopharma Global's earnings last quarter?: POINT Biopharma Global Inc. (NASDAQ:PNT) issued its quarterly earnings data on Monday, August, 14th. The company reported ($0.24) earnings per share for the quarter, topping analysts' consensus estimates of ($0.29) by $0.05. The firm had revenue of $4.87 million for the quarter, compared to analyst estimates of $8.50 million.

What is POINT Biopharma Global's stock symbol?: POINT Biopharma Global trades on the NASDAQ under the ticker symbol "PNT."
How do I buy shares of POINT Biopharma Global?: Shares of PNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is POINT Biopharma Global's stock price today?: One share of PNT stock can currently be purchased for approximately $6.69.
How much money does POINT Biopharma Global make?: POINT Biopharma Global (NASDAQ:PNT) has a market capitalization of $707.07 million and generates $226.58 million in revenue each year. The company earns $98.29 million in net income (profit) each year or $0.87 on an earnings per share basis.
How many employees does POINT Biopharma Global have?: The company employs 129 workers across the globe.
How can I contact POINT Biopharma Global?: POINT Biopharma Global's mailing address is 200 BERKELEY STREET 18TH FLOOR, BOSTON MA, 02116. The official website for the company is www.pointbiopharma.com. The company can be reached via phone at 64-7812-2417.

This page (NASDAQ:PNT) was last updated on 10/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial